ADC Therapeutics S.A.
NYSE:ADCTBiotechnology
-$0.02 today
- Market cap
- $192.71M
- Beta
- 1.77
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$0.89
Volume 1.17M
Average 1.68M
ADCT Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
ADC Therapeutics S.A.NYSE: ADCT
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue dips below year-ago levels
Q1 FY2026 revenue of $20.85M fell 9.5% year over year, behind the +4.4% change in trailing-twelve-month revenue. Sequentially, it fell 9.6% from the prior quarter. Over 3 fiscal years it compounded at -27.1% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether revenue reaches the consensus estimate from 1 analysts of $80.45M (-1.1%) for the fiscal year ending Dec 2026, a slowdown from the +14.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $20.85M-9.6% QoQ
- Last fiscal yearDec 2025
- $81.36M+14.9% YoY
- LTMMar 2026
- $79.18M+4.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -9.5% | +0.3% | +9.7 pp |
| 1 year | +14.9% | -1.1% | -16.0 pp |
| 3-year CAGR | -27.1% | +33.1% | +60.1 pp |
| 5-year CAGR | +30.5% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 81.36M USD
- Year-over-year change
- +14.9%
- 4-year CAGR
- +24.4%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 81.36M | +14.9% |
| FY2024 | 2024-12-31 | 70.84M | +1.8% |
| FY2023 | 2023-12-31 | 69.56M | -66.9% |
| FY2022 | 2022-12-31 | 209.91M | +518.9% |
| FY2021 | 2021-12-31 | 33.92M | — |
Revenue vs competitors
How ADCT compares with its peers on the latest reported figures
- ADCT's LTM Mar 2026 revenue of $79.18M is the 3rd highest of the 10 companies compared; the peer median is $14.78M.
- Its year-over-year change of +4.4% is the 6th highest of 8, against a peer median of +123.1%.
- Over three fiscal years its annual growth of -27.1% compares with a peer median of +130.2%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $92.59M | +927.5% | +130.2% | |
| LTM Mar 2026 | $88.24M | +383560.9% | +200.9% | |
| LTM Mar 2026 | $79.18M | +4.4% | -27.1% | |
| LTM Mar 2026 | $69.64M | +123.1% | +610.3% | |
| LTM Mar 2026 | $63.5M | +146.9% | +71.2% | |
| LTM Mar 2026 | $14.78M | +54.6% | -0.3% | |
| LTM Mar 2026 | $9.89M | — | — | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $7.4M | -63.1% | — |
| LTM Mar 2026 | $1.85M | -46.2% | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $0 | — | — |
| Peer median (excluding ADCT) | $14.78M | +123.1% | +130.2% | |
Competitors are the stored peer set for ADCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 33.92M | 209.91M | 69.56M | 70.84M | 81.36M |
| Cost of Revenue | 1.39M | 3.3M | 2.53M | 5.95M | 7.67M |
| Gross Profit | 32.52M | 206.61M | 67.03M | 64.89M | 73.68M |
| Gross Margin | 95.9% | 98.4% | 96.4% | 91.6% | 90.6% |
| Research & Development | 158M | 186.46M | 127.13M | 109.63M | 104.01M |
| Selling, General & Admin | 136.24M | 143.49M | 105.89M | 85.91M | (6.82M) |
| Operating Expenses | 294.24M | 329.95M | 233.02M | 195.54M | 182.06M |
| Depreciation & Amortization | 2.63M | 2.39M | 3.27M | 3.28M | 1.88M |
| EBITDA | (230.54M) | (107.7M) | (145.83M) | (102.65M) | (89.27M) |
| EBITDA Margin | -679.7% | -51.3% | -209.6% | -144.9% | -109.7% |
| Operating Income | (261.72M) | (123.34M) | (165.99M) | (130.65M) | (108.38M) |
| Operating Margin | -771.6% | -58.8% | -238.6% | -184.4% | -133.2% |
| Interest Income | 66K | 2.57M | 10.54M | 12.27M | 8.81M |
| Interest Expense | 18.34M | 36.73M | 46.33M | 50.21M | 51.63M |
| Other Income / Expenses | 10.22M | (33.56M) | (34.96M) | (27.03M) | (34.4M) |
| Income Before Tax | (251.51M) | (156.9M) | (200.95M) | (157.68M) | (142.78M) |
| Pre-Tax Margin | -741.5% | -74.7% | -288.9% | -222.6% | -175.5% |
| Income Tax Expense | (21.48M) | 227K | 39.11M | 166K | (157K) |
| Net Income | (230.03M) | (157.13M) | (240.05M) | (157.85M) | (142.62M) |
| Net Margin | -678.2% | -74.9% | -345.1% | -222.8% | -175.3% |
| EPS (Basic) | (3.00) | (1.99) | (2.94) | (1.62) | (1.12) |
| EPS (Diluted) | (3.00) | (1.99) | (2.94) | (1.62) | (1.12) |
| Weighted Avg Shares | 76.75M | 78.15M | 81.71M | 97.16M | 127.07M |
| Weighted Avg Shares (Diluted) | 76.75M | 78.15M | 81.71M | 97.16M | 127.07M |
ADC Therapeutics S.A.
NYSE:ADCT
Intrinsic Alpha fair value
Locked
Current Price
$1.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.